Grifols SA - ADR - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GRFS Nasdaq 2836 https://www.grifols.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Grifols SA - ADR

Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients - Nov 16th, 2023 10:00 am
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency - Nov 15th, 2023 1:00 pm
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023 - Nov 6th, 2023 1:00 pm
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript - Nov 3rd, 2023 6:56 pm
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD - Oct 24th, 2023 10:30 pm
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins - Oct 19th, 2023 12:00 pm
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564 - Sep 28th, 2023 12:00 pm
GRFS or STVN: Which Is the Better Value Stock Right Now? - Sep 14th, 2023 3:40 pm
Grifols (GRFS) Upgraded to Strong Buy: What Does It Mean for the Stock? - Sep 12th, 2023 4:00 pm
Should Value Investors Buy Grifols (GRFS) Stock? - Sep 12th, 2023 1:40 pm
Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics - Aug 1st, 2023 12:00 pm
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients - Jul 20th, 2023 12:15 pm
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis - Jul 18th, 2023 12:00 pm
Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency - Jul 13th, 2023 12:00 pm
Grifols shares soar on possible sale of $1.5 billion stake in Shanghai RAAS - Jun 14th, 2023 8:56 am
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD - May 11th, 2023 12:30 pm
Why Shares of Grifols Were Up Tuesday - May 9th, 2023 7:39 pm
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - Apr 18th, 2023 2:30 pm
Are Investors Undervaluing Grifols (GRFS) Right Now? - Mar 15th, 2023 1:40 pm
Grifols (GRFS) Upgraded to Strong Buy: Here's Why - Mar 7th, 2023 5:00 pm